Abstract
Depression and anxiety are highly comorbid with chronic obstructive pulmonary disease (COPD) and are associated with poor treatment adherence, increased rates of physical disability, functional disability, mortality, healthcare costs, and a worsening quality of life. Despite its prevalence, there is a dearth of research on psychological treatments for depressed and/or anxious patients with COPD. This review examines the current evidence for psychological treatments for depression and anxiety in COPD, structured within the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework, in an effort to highlight the current practice and research needs for this important and complex patient population.
Keywords: Ambulatory care, anxiety, chronic obstructive pulmonary disease, depression, primary care, psychotherapy, REAIM
Current Respiratory Medicine Reviews
Title:Depression and Anxiety in Patients with COPD: A Focus on Psychological Treatments in Ambulatory Care Settings
Volume: 8 Issue: 2
Author(s): Joseph Mignogna, Jeffrey A. Cully
Affiliation:
Keywords: Ambulatory care, anxiety, chronic obstructive pulmonary disease, depression, primary care, psychotherapy, REAIM
Abstract: Depression and anxiety are highly comorbid with chronic obstructive pulmonary disease (COPD) and are associated with poor treatment adherence, increased rates of physical disability, functional disability, mortality, healthcare costs, and a worsening quality of life. Despite its prevalence, there is a dearth of research on psychological treatments for depressed and/or anxious patients with COPD. This review examines the current evidence for psychological treatments for depression and anxiety in COPD, structured within the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework, in an effort to highlight the current practice and research needs for this important and complex patient population.
Export Options
About this article
Cite this article as:
Joseph Mignogna, Jeffrey A. Cully , Depression and Anxiety in Patients with COPD: A Focus on Psychological Treatments in Ambulatory Care Settings, Current Respiratory Medicine Reviews 2012; 8 (2) . https://dx.doi.org/10.2174/157339812799859743
DOI https://dx.doi.org/10.2174/157339812799859743 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Effect of Rehabilitative Exercise Training on Peripheral Muscle Remodelling in Patients with COPD: Targeting Beyond the Lungs
Current Drug Targets Cardiovascular and Fluid Volume Control in Humans in Space
Current Pharmaceutical Biotechnology A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Formulation, Evaluation and Optimization of Self-Nano Emulsifying Drug Delivery System Containing Felodipine
Micro and Nanosystems The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Antiplatelet Therapy in TAVI: Current Clinical Practice and Recommendations
Current Pharmaceutical Design Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Mesenchymal Stem Cells Targeting of Systemic Disorders in Age-related Macular Degeneration
Current Tissue Engineering (Discontinued) Genetic Engineering in Allotransplantation of Vascularized Organs
Current Gene Therapy Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design